# CJC-1295 Ipamorelin Research: Twenty-Two Findings Indexed by Mechanism, Species, and Outcome

> CJC-1295 ipamorelin mechanism of action, key preclinical and human studies, side effects in published trials, selectivity data, and comparative research. Peer-reviewed literature indexed.

## Growth Hormone Secretagogue Research Background

Growth hormone secretagogues (GHS) constitute a class of compounds that stimulate GH secretion from the anterior pituitary without administering exogenous GH directly. The Endocrine Society's 2023 scientific statement confirmed that peak GH secretion declines approximately 50% every 7–10 years after puberty.[20] GHS trials in older adults restored pulsatile GH secretion to levels observed in 20-to-30-year-olds, with mild insulin resistance as the primary recurring adverse signal.[17][20]

## CJC-1295 Ipamorelin Mechanism of Action

CJC-1295 binds the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, activating adenylate cyclase, elevating intracellular cAMP, and activating protein kinase A. CJC-1295's albumin-bioconjugation (DAC form) extends plasma residence to approximately 6–8 days; the compound was detectable in rat plasma beyond 72 hours post-injection and produced a 4-fold GH AUC increase over native hGRF(1-29).[2]

Ipamorelin binds GHS-R1a, triggering acute pulsatile GH release by (a) directly stimulating somatotroph GH release, (b) antagonizing hypothalamic somatostatin release, and (c) stimulating additional hypothalamic GHRH secretion — three synergistic sub-mechanisms confirmed across human, rat, swine, bovine, and canine models.[13]

## Key Studies

**Ionescu and Frohman (2006) — Human GH pulsatility under CJC-1295.[1]** 60–90 µg/kg SC in healthy men elevated mean GH 46%, IGF-1 45%, and basal GH 7.5-fold. Pulsatility preserved.

**Jetté et al. (2005) — DAC mechanism.[2]** 4-fold GH AUC increase over native GHRH; albumin conjugate detectable 72+ hours post-SC-dose in rats.

**Raun et al. (1998) — Ipamorelin selectivity.[3]** No ACTH, cortisol, FSH, LH, prolactin, or TSH elevation at 200x GH ED50.

**Farhy and Veldhuis (2005) — GHS/GHRH synergy across five species.[13]** Supraadditive GH release; pulsatile pattern preserved under continuous GHS infusion.

**Sackmann-Sala et al. (2009) — Downstream proteomics in healthy men.[6]** Immunoglobulin-albumin fragment levels correlated linearly with IGF-1 elevation.

## CJC-1295 Ipamorelin Side Effects in Published Studies

Phase I trials for CJC-1295 reported injection-site reactions, transient facial flushing, peripheral edema, headache, and mild glucose changes at higher doses. No serious adverse events were recorded in published healthy-subject trials. Ipamorelin Phase I data confirmed selective GH release without cortisol or ACTH elevation.[3] GHS-independent adipogenic effects in GH-intact mice were observed with ipamorelin.[19]

## CJC-1295 with DAC vs No DAC: Half-Life Comparison

Native GRF(1-29) has a plasma half-life below 10–13 minutes due to DPP-IV N-terminal cleavage.[16] CJC-1295 with DAC: approximately 6–8 days (albumin-bound).[1][2] CJC-1295 without DAC: intermediate, approximately 30 minutes.

## Effects on Testosterone and Other Hormones

CJC-1295 published clinical trials did not report significant changes in testosterone, LH, or FSH. Ipamorelin confirmed no FSH or LH elevation at 200-fold above GH ED50.[3]

## Secretagogue Stimulation vs Exogenous HGH

Secretagogues preserve the IGF-1 negative feedback loop; exogenous rhGH bypasses pituitary regulation. MK-677 (25 mg/day for 28 days in 32 elderly subjects) increased mean 24-hour GH 97% ± 23% and raised IGF-1 to normal young-adult range, with fasting glucose rising from 5.4 to 6.8 mmol/L.[14]

## CJC-1295 Ipamorelin vs Sermorelin

Sermorelin is GRF(1-29) without DPP-IV-resistant substitutions or DAC albumin-binding; half-life below 30 minutes. CJC-1295 DAC: approximately 6–8 days.[16][2] No published head-to-head human comparison exists.

## References

[1] Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[2] Jetté L, et al. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[3] Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/
[6] Sackmann-Sala L, et al. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[13] Farhy LS, Veldhuis JD. Am J Physiol Regul Integr Comp Physiol. 2005;288(5):R1649-R1663. https://pubmed.ncbi.nlm.nih.gov/15718392/
[14] Chapman IM, et al. J Clin Endocrinol Metab. 1996;81(12):4249-4257. https://pubmed.ncbi.nlm.nih.gov/8954023/
[16] Memdouh S, et al. Drug Test Anal. 2021;13(7):1233-1247. https://pubmed.ncbi.nlm.nih.gov/34665524/
[17] Smith RG, Thorner MO. J Gerontol A Biol Sci Med Sci. 2023;78(6):975-983. https://pmc.ncbi.nlm.nih.gov/articles/PMC10272984/
[19] Lall S, et al. Biochem Biophys Res Commun. 2001;280(1):132-138. https://pubmed.ncbi.nlm.nih.gov/11162489/
[20] Cappola AR, et al. J Clin Endocrinol Metab. 2023;108(8):1835-1874. https://pmc.ncbi.nlm.nih.gov/articles/PMC11491666/
[21] Tausendfreund O, et al. Growth Horm IGF Res. 2024;75:101584. https://pubmed.ncbi.nlm.nih.gov/38489867/
[22] Timms M, et al. Drug Test Anal. 2019;11(4):593-601. https://pubmed.ncbi.nlm.nih.gov/30489688/

---

Twenty-two studies across six species, indexed as a folk-almanac of the CJC-1295 ipamorelin literature — no clinic behind the cordel, no vendor behind the broadside.